Related by context. All words. (Click for frequent words.) 76 hematologic toxicity 73 peripheral sensory neuropathy 72 neutropenia febrile neutropenia 71 neutropaenia 71 hematologic adverse 71 leucopenia 70 fatigue asthenia 70 FluCAM arm 70 plus 5-FU/LV 70 febrile neutropenia 69 Toxicities 69 haematologic 69 Infusion Reactions Severe 68 sensory neuropathy 68 neutropenia dehydration dyspnea 68 lymphopenia 68 DLTs 67 anemia neutropenia 67 hypophosphatemia 67 thrombocytopenia neutropenia 67 neutropenia thrombocytopenia 67 hematological toxicity 67 ALT flares 66 thromboembolic events 66 non hematological toxicities 66 leukopenia 66 transaminase elevations 66 QTc prolongation 66 hematological adverse 66 unresectable HCC 66 â ‰ ¥ 66 TORISEL 66 Dermatologic toxicities 66 relapsed MM 66 biologic DMARD 66 oxycodone CR 66 colorectal adenoma 66 cisplatin gemcitabine 65 myelosuppression 65 oral Hycamtin 65 intravascular hemolysis 65 mitoxantrone plus 65 Tarceva TM 65 events AEs 65 renal toxicity 65 symptomatic VTE 65 mucosal inflammation 65 PREZISTA r arm 65 severe hypersensitivity reactions 65 laboratory abnormalities 65 teriflunomide 65 Serious adverse reactions 65 Ophena TM 65 ACTEMRA TM 65 hematologic adverse reactions 65 DOXIL 65 non metastatic osteosarcoma 65 hematological toxicities 65 locoregional recurrence 65 Hematologic 65 MCyR 65 postoperative chemotherapy 65 neutropenic sepsis 65 Amrubicin 65 nadroparin 64 hypomagnesemia 64 liver transaminases 64 papillary renal cell carcinoma 64 recurrent DVT 64 neutropenia anemia 64 forodesine 64 5-FU/LV 64 dose cohort 64 tumor lysis syndrome 64 ximelagatran 64 INCB# [003] 64 solifenacin 64 CLL SLL 64 mg/m2 dose 64 incidence ≥ 64 4mg/kg 64 paresthesias 64 doxorubicin cyclophosphamide 64 dermatologic toxicities 64 genitourinary GU 64 mg kg dose 64 idiopathic thrombocytopenic purpura 64 morphometric vertebral fractures 64 elevated ALT 64 octreotide LAR 64 gastrointestinal perforation 64 cobiprostone 64 Xelox 64 ARCALYST ® 64 Erythropoietic therapies may 64 CIMZIA ™ 64 pamidronate 64 tuberous sclerosis TS 64 HuMax EGFr 64 demonstrated antitumor activity 64 headache abdominal pain 64 hematologic toxicities 64 pimecrolimus cream 64 receiving XGEVA 64 ara C 64 mycophenolate mofetil 64 alpha interferons 64 FOLFOX4 63 estramustine 63 pyrexia mucositis sepsis febrile 63 myalgia arthralgia 63 invasive candidiasis 63 ancrod 63 evaluating tivozanib 63 doxorubicin docetaxel 63 paclitaxel carboplatin 63 hyperphenylalaninemia HPA due 63 Elitek 63 cough dyspnea 63 Hycamtin ® 63 salmeterol fluticasone 63 ® lenalidomide 63 melphalan prednisone 63 toxicities 63 immune thrombocytopenic purpura ITP 63 metastatic bone 63 Xeloda ® 63 pain palliation 63 intermittent dosing 63 headache nasopharyngitis 63 pheochromocytoma 63 nasopharyngitis headache 63 #mg dose [002] 63 cinacalcet 63 Cimzia TM 63 Febrile neutropenia 63 metastatic GIST 63 NEUPOGEN 63 vitreous floaters 63 Neutropenia 63 conjunctival hyperemia 63 hypercalcemia 63 BR.# 63 histologic subtype 63 prednisone prednisolone 63 thrombocytopenia 63 external genital lesions 63 nonmetastatic prostate cancer 63 anaplastic astrocytomas 63 subependymal giant cell 63 cardiac toxicity 63 acute GvHD 63 Aloxi injection 63 EXJADE 63 dermatologic reactions 63 pancreatic prostate 63 severe exacerbations 63 dacarbazine DTIC 63 mycophenolate mofetil MMF 63 TELINTRA 63 Flu Cy 63 severe neutropenia 63 desvenlafaxine succinate 63 non hematologic toxicities 63 hematologic abnormalities 63 visilizumab 63 bone marrow suppression 63 ACAPODENE 63 corticosteroid therapy 63 Neulasta ® 63 adverse reactions ≥ 63 neutropenia 63 acromegalic patients 63 Fludara 63 non splenectomized 63 TMC# r 63 refractory gout 63 PREZISTA r 63 mcg BID 63 Gastrointestinal GI 63 grade cervical intraepithelial 63 TNF antagonist 63 anthracycline taxane 63 thromboembolic 63 Dacogen injection 62 symptomatic paroxysmal AF 62 budesonide foam 62 GOUT 62 flutamide 62 nephrotoxicity 62 EGFRIs 62 recurrent glioblastoma 62 leukemia AML 62 SPRYCEL ® 62 Folfox 62 Archexin 62 CYT# potent vascular disrupting 62 elotuzumab 62 MAGE A3 ASCI 62 diarrhea vomiting nausea 62 HoFH 62 deep venous thromboses 62 biochemical relapse 62 hepatotoxicity 62 biliary tract cancer 62 TTF Therapy 62 ARCOXIA 62 artery stenosis 62 oral allopurinol 62 experienced hypomagnesemia 62 Stent thrombosis 62 Dasatinib 62 delayed CINV 62 moderately emetogenic 62 thrombocytopenia anemia 62 FOLFIRI alone 62 receptor tyrosine kinase inhibitor 62 Bezielle 62 intracranial hemorrhage ICH 62 idraparinux 62 chronic GVHD 62 occlusion PAO 62 peritumoral brain edema 62 Doxil ® 62 cytopenias 62 hypocalcemia 62 ACAPODENE TM 62 venous thromboembolic events 62 adalimumab Humira 62 CTAP# Capsules 62 headache nausea diarrhea 62 cutaneous squamous cell carcinoma 62 mcg QD 62 Amgen Neulasta R 62 TMP SMX 62 severe oral mucositis 62 dysplastic lesions 62 Irinotecan 62 events SAEs 62 CIMZIA TM certolizumab pegol 62 recurrent metastatic 62 palmar plantar 62 overactive bladder syndrome 62 TAXOTERE ® 62 mucositis 62 APTIVUS r 62 Randomized Double blind 62 HbA 1c levels 62 Retreatment 62 MYCAMINE 62 piperacillin tazobactam 62 angioneurotic edema 62 dasatinib Sprycel ® 62 diarrhea nausea vomiting 62 HeFH 62 alfa 2a 62 ibandronate 62 neutropenic fever 62 clevidipine 62 Q#IR 62 arthralgias 62 CHOP chemotherapy 62 certolizumab 62 novel VDA molecule 62 Randomized Phase 62 Vidaza azacitidine 62 Nilotinib 62 #mg/m# [001] 62 MGd 62 nonvertebral fracture 62 docetaxel Taxotere 62 chronic idiopathic thrombocytopenic purpura 62 ß blockers 62 Hepatocellular Carcinoma HCC 62 limiting toxicity 62 hepatorenal syndrome 61 Adverse events 61 prucalopride 61 hypercholesterolaemia 61 Infusion reactions 61 adriamycin 61 pulmonary exacerbation 61 Darusentan 61 Hepatotoxicity 61 statin monotherapy 61 hyperbilirubinemia 61 docetaxel chemotherapy 61 treatment naïve genotype 61 VFEND 61 pancytopenia 61 nonvertebral fractures 61 retinal vein occlusion induced 61 ATACAND 61 gout flares 61 hA# 61 urate lowering 61 asthenia pain 61 BRIM2 61 dosing cohort 61 myopathy rhabdomyolysis 61 oral diclofenac 61 recurrent glioblastoma multiforme 61 platelet inhibitor 61 oral levofloxacin 61 plasma kallikrein inhibitor 61 CYPHER Stent 61 malignancy HCM 61 denileukin diftitox 61 unresectable stage 61 painful diabetic neuropathy 61 PAOD 61 Vicinium TM 61 tumor necrosis 61 arterial thromboembolic events 61 somatostatin analog 61 definite stent thrombosis 61 palifermin 61 stage IIIb IV 61 ALA PDT 61 O PPDS 61 R# #mg BID 61 OAB symptoms 61 endometrial hyperplasia 61 mg BID dose 61 thromboembolic complications 61 sitaxsentan 61 docetaxel Taxotere ® 61 Teriflunomide 61 tamoxifen Nolvadex ® 61 Known hypersensitivity 61 Raptiva ® 61 myelodysplastic myeloproliferative diseases 61 virologic breakthrough 61 selective phosphodiesterase 61 INVEGA ® 61 locoregional disease 61 metaglidasen 61 Mitoxantrone 61 dalteparin 61 rosuvastatin #mg 61 PASI scores 61 benign prostatic hypertrophy BPH 61 hemorrhagic cystitis 61 fatigue diarrhea nausea 61 deferiprone 61 partial remissions 61 ALGRX 61 divalproex sodium 61 acute coronary syndromes ACS 61 steroid dexamethasone 61 GORE TAG Device 61 nausea vomiting headache 61 anthracyclines taxanes 61 Sudhir Agrawal D.Phil 61 DETROL LA 61 ZACTIMA 61 histological subtype 61 interferon ribavirin 61 gadobutrol 61 rFVIIa 61 non valvular atrial 61 pleural effusion 61 tapentadol ER 61 Pemetrexed 61 Eltrombopag 61 cerebrovascular events 61 secondary hyperparathyroidism 61 Fibrillex TM 61 NNT = 61 metastatic malignant 61 parathyroid carcinoma 61 Thal Dex 61 FUSILEV enhances 61 Atrasentan 61 Stomatitis 61 RLY# 61 5 lipoxygenase inhibitor 61 histologically confirmed 61 metastatic renal 61 BENICAR HCT 61 TRAIL R1 61 xanthine oxidase inhibitor 61 TO AVOID PREGNANCY WHILE 61 advanced adenomas 61 NSAID induced 61 virological failure 61 Zemplar Capsules 61 Pivotal Phase 61 complete cytogenetic response 61 brivaracetam 61 beclomethasone dipropionate 61 gemcitabine carboplatin 61 hydroxymethyl coenzyme 61 R lenalidomide 61 Pivotal Phase III 61 venous stasis ulcers 61 nonmetastatic 61 LHRH receptor positive 61 refractory NSCLC 61 discontinuations due 61 Peg IFN 61 docetaxel Taxotere R 61 Warfarin Coumadin 61 TELCYTA 61 infusion reactions 61 Ozarelix 61 postsurgical pain 61 CALGB # [002] 61 vandetanib 61 baminercept 60 chemoradiotherapy 60 Subgroup analysis 60 micafungin 60 LymphoStat B belimumab 60 posaconazole 60 del 5q MDS 60 variceal hemorrhage 60 ARB telmisartan 60 recurrent venous thromboembolism 60 Angioedema 60 skeletal metastases 60 Vandetanib 60 valsartan amlodipine 60 ankylosing spondylitis AS 60 treatment emergent adverse 60 Hypotension 60 heterozygous FH 60 midstage clinical 60 nadolol 60 included exfoliative dermatitis 60 Platinol ® 60 intravenous bisphosphonates 60 parecoxib 60 androgen suppression 60 6R BH4 60 metastatic malignant melanoma 60 AST ALT 60 pT3 60 receiving highly emetogenic 60 lintuzumab SGN 60 dual endothelin receptor antagonist 60 proton pump inhibitor PPI 60 ICD shocks 60 cabazitaxel 60 mg kg BID 60 superficial edema 60 Fludarabine 60 TEAEs 60 Navelbine 60 pouchitis 60 R Saizen R 60 EXPAREL TM 60 visceral metastases 60 MACCE 60 elevated IOP 60 antiemetics 60 Seroquel quetiapine fumarate 60 intracerebral hemorrhage 60 liposomal formulation 60 PROMACTA 60 subtrochanteric 60 sodium thiosulfate STS 60 refractory AML 60 acetonide FA 60 bisoprolol 60 AGILECT R 60 Amgen Neulasta ® 60 basal cell carcinoma BCC 60 PRTX 60 Triapine R 60 advanced adenoma 60 Anaplastic 60 CEQ# 60 G#DT 60 genotypic resistance 60 treatment naive genotype 60 chemotherapy cisplatin 60 mg/# h 60 Thrombocytopenia 60 infusional 5-FU/LV 60 squamous cell carcinoma SCC 60 Chemotherapy induced 60 lomitapide 60 reactogenicity 60 COPD exacerbation 60 Proxinium TM 60 IBS C 60 dexamethasone Decadron 60 nonhematologic adverse reactions 60 total thyroidectomy 60 placebo controlled Phase 60 precancerous cervical lesions 60 maximal doses 60 Adenomas 60 radiotherapy RT 60 selective A2A adenosine receptor 60 galiximab 60 TEMODAL 60 PRADAXA 60 Navelbine ® 60 cardiotoxic 60 VAPRISOL 60 fluoropyrimidine 60 Renal impairment 60 carcinoid tumors 60 B Cell Lymphoma 60 candidemia 60 sorafenib Nexavar 60 calcineurin inhibitor 60 pomalidomide 60 pathologic fractures 60 steroid refractory ulcerative 60 paclitaxel Taxol ® 60 STRIDE PD 60 SinuNase TM 60 Follicular Lymphoma 60 danazol 60 thrombocytopenic 60 tardive dyskinesia TD 60 fluorouracil leucovorin 60 locoregional 60 VIIBRYD 60 Insulin PH# 60 liver resection 60 stage IIIB 60 Vidaza ® 60 PRT# 60 TNF Tumor Necrosis Factor 60 fatigue abdominal pain 60 weekly subcutaneous injections 60 perioperative morbidity 60 chlorambucil 60 monoclonal antibody conjugated 60 microbiological eradication 60 azacytidine 60 ORENCIA ® 60 Kepivance 60 zalutumumab 60 Aggrastat ® tirofiban hydrochloride 60 proctitis 60 Hormone Refractory Prostate Cancer 60 Vascugel ® 60 androgen ablation 60 debulking surgery 60 prospectively stratified 60 pimecrolimus 60 sorafenib tablets 60 thalidomide Thalomid 60 DMARDS 60 polycythemia vera essential thrombocythemia 60 isoproterenol 60 Fluorouracil 60 maximally tolerated dose 60 Fludara ® 60 systemic corticosteroid 60 nicardipine 60 CA4P 60 malignant neoplasms 60 AEs 60 ZYVOX 60 thromboses 60 CIMZIA R 60 aflibercept VEGF Trap 60 RezularTM 60 Entereg R 60 CANCIDAS 60 Budesonide foam crofelemer 60 oral prodrug 60 conventional DMARDs 60 iniparib BSI 60 clinically meaningful reductions 60 Pruvel 60 sargramostim 60 daunorubicin 60 β blockers 60 metastatic bladder 60 Aflibercept 60 Atypical Hemolytic Uremic Syndrome 60 Pegloticase 60 cervical intraepithelial neoplasia 59 HMG CoA reductase inhibitors 59 active ankylosing spondylitis 59 ALT elevation 59 bortezomib Velcade 59 lenalidomide dexamethasone 59 standard chemotherapy regimen 59 IV NSCLC 59 lenalidomide Revlimid R 59 myeloproliferative diseases 59 post herpetic neuralgia PHN 59 extrapyramidal symptoms 59 prednisone prednisolone plus 59 CIN2 + 59 gross hematuria 59 FOLFOX6 59 pericardial effusion 59 tumor xenograft models 59 Juvenile Idiopathic Arthritis 59 follicular lymphoma FL 59 LEP ETU 59 fluvastatin 59 gastroduodenal 59 Intravitreal 59 metastatic neuroendocrine tumors 59 Zorbtive TM 59 EOquin TM phase 59 GSK# [001] 59 Helicobacter pylori eradication 59 containing abacavir 59 nephrotoxic 59 adjuvant radiotherapy 59 otamixaban 59 Eculizumab 59 neoadjuvant treatment 59 topically administered 59 nosocomial pneumonia 59 peginterferon alfa 59 tigecycline 59 aprepitant 59 gastrointestinal ulcers 59 Elagolix 59 riociguat 59 esophagitis 59 gemcitabine chemotherapy 59 cutaneous lupus 59 aplastic anemia AA 59 antiretroviral naïve 59 pegylated liposomal doxorubicin 59 cisplatin chemotherapy 59 palonosetron 59 relapsing multiple sclerosis 59 RLAI 59 smoldering myeloma 59 Pharmacokinetics PK 59 LYSTEDA 59 acneform rash 59 CYP #A# 59 Ribavirin causes 59 basal bolus regimen 59 hormone receptor negative 59 proximal DVT 59 diclofenac sodium 59 complement inhibitor eculizumab 59 taxane resistant 59 endophthalmitis 59 LHRH agonists 59 PEGINTRON TM 59 gemcitabine Gemzar ® 59 gastrointestinal adverse reactions 59 rheumatoid arthritis osteoarthritis ankylosing 59 topical diclofenac 59 BRAF inhibitor 59 antiandrogen 59 TheraCIM h R3 59 intravitreal injections 59 Denufosol 59 coadministration 59 NMIBC 59 constipation nausea 59 graft dysfunction 59 Fulvestrant 59 superficial bladder cancer 59 Myelodysplastic Syndrome MDS 59 oblimersen 59 onset diabetes mellitus 59 phase IIb study 59 hemorrhagic complications 59 REMINYL ® 59 Dyloject TM 59 efalizumab 59 thromboembolism 59 Xanafide 59 oral deforolimus 59 GnRH agonist 59 liposomal amphotericin B 59 Omacetaxine 59 PEGylated interferon beta 1a 59 astrocytomas 59 placebo controlled clinical 59 chemotherapy induced neutropenia 59 mucocutaneous reactions 59 nonmelanoma skin cancers 59 gastrointestinal toxicity 59 symptomatic intracranial hemorrhage 59 Alocrest 59 events TEAEs 59 pT2 59 efaproxiral 59 recurrent VTE 59 PEGylated anti 59 Adjuvant chemotherapy 59 sunitinib malate 59 bovine thrombin 59 thrombophlebitis 59 atrial tachyarrhythmias 59 Initiated Phase 59 gastrin analogue TT 59 kidney urologic 59 trospium 59 GEMZAR 59 related hematological toxicity 59 AA Amyloidosis 59 INVEGA ™ 59 cytogenetic abnormalities 59 Telintra 59 postoperative morbidity 59 favorable tolerability 59 vitamin B# folic acid 59 romiplostim 59 vinorelbine 59 Panzem R NCD 59 CINTREDEKIN BESUDOTOX 59 olmesartan 59 GRN# 59 Vaprisol 59 basiliximab 59 insomnia somnolence 59 keloid scarring 59 EDEMA3 trial 59 Zarnestra 59 DOXIL ® 59 Dacogen decitabine 59 plus prednisone 59 hypersensitivity reactions 59 Aptivus ® 59 oral antidiabetes 59 sJIA 59 kallikrein 59 metastatic colorectal 59 REVLIMID ® 59 stage IIIb 59 azilsartan medoxomil 59 recurrent NSCLC 59 PEGylated Fab fragment 59 ZACTIMA TM ZD# 59 R sorafenib tablets 59 immunomodulatory therapy 59 NNRTI resistance 59 torsemide ER 59 invasive ductal 59 intravesical 59 OPAXIO 59 liposomal doxorubicin 59 portal vein thrombosis 59 AGHD 59 patients receiving ERBITUX 59 renal insufficiency 59 NLX P# 59 Tavocept 59 hypertrophic scars 59 #mg BID [003] 59 Postoperative complications 59 TNF antagonist therapy 59 including eniluracil ADH 59 Tolvaptan 59 hepatic adverse 59 Coadministration 59 systemic hypotension 59 IOP lowering 59 nitrofurantoin 59 infusional 59 Enzastaurin 59 hepatic enzyme 59 BCG refractory 59 RECORD1 59 ritonavir boosted 59 CTEPH 59 malignant ascites 59 alvespimycin 59 cilengitide 59 Hsp# Inhibitor 59 trastuzumab Herceptin R 59 Peginterferon alfa 2b 59 idarubicin 59 Noxafil 59 octreotide 59 ribavirin RBV 59 Glioblastoma Multiforme 59 Platinol ® cisplatin 59 Natalizumab 59 MNTX 59 adjuvant cisplatin 59 dextofisopam 59 neoplasias 59 unfavorable cytogenetics 59 enterocolitis 59 graft occlusion 59 gallium nitrate 59 FOLFIRI 59 juvenile idiopathic arthritis 59 Mg Uk 59 Tumor shrinkage 59 NEVO ™ 59 venlafaxine XR 59 concomitant medications 59 Secondary endpoints 59 iniparib 59 vapreotide acetate 59 VELCADE melphalan 59 symptomatic intracranial 59 R#/MEM # 59 adrenocortical cancer 59 BN# [004] 59 neurologic complications 59 baseline LDH 59 relapsed refractory multiple myeloma 59 non selective NSAIDs 59 glycated hemoglobin levels 59 Combination REOLYSIN R 59 MabThera Rituxan 58 Acneform rash occurred 58 cytogenetic responses 58 severe gastroparesis 58 MabCampath 58 hypoglycemic events 58 GABITRIL 58 AEGR 58 leiomyomas 58 Initiate Phase 58 tramiprosate Alzhemed TM 58 T1c 58 Camptosar ® 58 Traficet EN 58 mapatumumab 58 Stage IIB 58 ocular adverse 58 Metastatic Prostate Cancer 58 cholecystitis 58 esophageal carcinoma 58 post thrombotic syndrome 58 Lamotrigine 58 grade cervical dysplasia 58 oxymorphone ER 58 EGFR HER2 58 ATL/TV# 58 receptor inhibitor 58 Taxol paclitaxel 58 MoxDuo TM IR 58 #mg/day [002] 58 favorable pharmacokinetic profile 58 mg Proellex 58 pertuzumab 58 CTA# Injection 58 RoACTEMRA 58 anaphylactic reactions bronchospasm 58 Vidofludimus 58 Castration Resistant Prostate Cancer 58 FROVA 58 smoldering multiple myeloma 58 hepatic toxicity 58 mixed hyperlipidemia 58 transitional cell carcinoma 58 psoriatic arthritis PsA 58 cytoreduction 58 mg q#h 58 idiopathic thrombocytopenic purpura ITP 58 cSSSIs 58 somnolence dizziness 58 Cetuximab Erbitux 58 intracranial hemorrhage bleeding 58 HPV-#/# 58 myocardial infarction ventricular fibrillation 58 diabetic gastroparesis 58 GAMMAGARD 58 megestrol acetate 58 diabetic neuropathic pain 58 Tindamax R 58 adenoma recurrence 58 spinal cord compression 58 occlusive disease 58 Patients Treated With 58 EDARBI 58 R adalimumab 58 % AST SGOT 58 Paraplatin ® 58 intra abdominal abscess 58 gastric adenocarcinoma 58 Gemzar gemcitabine 58 Paroxysmal Nocturnal Hemoglobinuria PNH 58 PENTASA 58 beta 1a 58 pegylated interferon alpha 58 tocilizumab 58 follicular lymphomas 58 hemoptysis 58 FOLFOX6 chemotherapy regimen 58 paroxysmal AF 58 HBeAg negative 58 Non inferiority 58 REMICADE ® 58 ARCALYST ® rilonacept 58 Proquin XR 58 Relapsed Multiple Myeloma 58 antiangiogenic therapy 58 interferon alfa 2b 58 MYLOTARG 58 advanced hepatocellular carcinoma 58 sapacitabine CYC# 58 Refractory Hodgkin Lymphoma 58 deferoxamine 58 Pharmacokinetic parameters 58 Panzem R 58 oral candidiasis 58 lupus nephritis 58 ecchymosis 58 knee osteoarthritis OA 58 alvimopan 58 venous thromboembolic disease 58 heavily pretreated 58 diabetic peripheral neuropathy 58 capillary leak 58 double blinded placebo 58 pneumonitis 58 Dose Ranging Study 58 fallopian tube carcinoma 58 opioid induced bowel dysfunction 58 Tasimelteon 58 Soft Tissue Sarcoma 58 EFFEXOR XR 58 Parathyroid Hormone 58 IMiDs 58 adverse cytogenetics 58 Carotid endarterectomy 58 phase Ib 58 Torisel 58 drug ISA# 58 colesevelam HCl 58 rheumatoid arthritis psoriatic arthritis 58 hyperprolactinemia 58 mg administered orally 58 IRX 2 58 gastrointestinal stromal 58 acute HAE attacks 58 Mg Usa 58 formerly LymphoStat B 58 FRAGMIN 58 caspofungin 58 finasteride Proscar 58 colorectal carcinomas 58 AGILECT ® 58 carboplatin paclitaxel 58 intravenous methylnaltrexone 58 fosbretabulin 58 discontinuations 58 Prosaptide 58 Antitumor Activity 58 Interferon alfa 58 Pegasys peginterferon alfa 2a 58 hypopituitarism 58 hypoglycaemic episodes 58 topical gel formulation 58 pulmonary metastases 58 urothelial carcinoma 58 dasatinib Sprycel 58 levodopa induced 58 neratinib 58 erythema redness 58 postoperative complication 58 refractory chronic lymphocytic 58 BANZEL 58 interstitial pneumonia 58 antibody MAb 58 Arranon 58 dextromethorphan quinidine 58 anaplastic astrocytoma 58 TNF alpha inhibitor 58 cyclophosphamide methotrexate 58 sorafenib Nexavar ® 58 crizotinib PF # 58 pegylated interferon peg IFN 58 venous thromboembolisms 58 Safinamide 58 pulmonary toxicity 58 Thrombotic events 58 TNF blocker therapy 58 KAPIDEX 58 Prolongs Survival 58 Raptiva R 58 alpha 2a 58 investigational monoclonal antibody 58 autoantibody positive 58 prolonged QT interval 58 Anthracycline 58 thromboembolic disease 58 dose titration 58 aripiprazole Abilify 58 LNG IUS 58 Hematologic toxicity 58 Increlex ® 58 elevated LDH 58 olanzapine LAI 58 atazanavir ritonavir 58 Aryplase 58 diarrhea predominant irritable 58 randomized Phase IIb 58 rilonacept 58 radioiodine therapy 58 malignant neoplasm 58 chronic thromboembolic pulmonary